• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Quinlan James P. claimed ownership of 129,147 shares (SEC Form 3)

    12/31/24 4:18:44 PM ET
    $MDCX
    Get the next $MDCX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Quinlan James P.

    (Last) (First) (Middle)
    300 CONSHOHOCKEN STATE ROAD
    SUITE 200

    (Street)
    W. CONSHOHOCKEN PA 19428

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    12/31/2024
    3. Issuer Name and Ticker or Trading Symbol
    Medicus Pharma Ltd. [ MDCX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Shares, no par value ("Common Shares") 129,147 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) (1) 10/24/2028 Common Shares 125,000 $0.81(2) D
    Stock Option (right to buy) (3) 12/17/2029 Common Shares 20,000 $2.75(4) D
    Warrants (right to buy) (5) 11/15/2029 Common Shares 24,000 $4.64 D
    Explanation of Responses:
    1. The option has vested and is exercisable as of the date hereof.
    2. Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.
    3. The option was granted on December 17, 2024. The option is scheduled to vest quarterly in four equal installments over one year.
    4. Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.
    5. The warrants are exercisable as of the date hereof.
    Remarks:
    Exhibit List - Exhibit 24.1 - Power of Attorney
    /s/ James Quinlan 12/31/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MDCX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDCX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MDCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 3 filed by new insider Mehmud Faisal

      3/A - Medicus Pharma Ltd. (0001997296) (Issuer)

      4/3/25 6:52:09 PM ET
      $MDCX
    • Amendment: New insider Bokhari Raza claimed ownership of 793,173 shares (SEC Form 3)

      3/A - Medicus Pharma Ltd. (0001997296) (Issuer)

      2/10/25 4:55:32 PM ET
      $MDCX
    • Amendment: SEC Form 3 filed by new insider May Sara R.

      3/A - Medicus Pharma Ltd. (0001997296) (Issuer)

      1/23/25 6:21:51 PM ET
      $MDCX

    $MDCX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Medicus Pharma Ltd.

      SCHEDULE 13G - Medicus Pharma Ltd. (0001997296) (Subject)

      5/15/25 3:20:39 PM ET
      $MDCX
    • SEC Form 253G2 filed by Medicus Pharma Ltd.

      253G2 - Medicus Pharma Ltd. (0001997296) (Filer)

      5/13/25 8:31:37 AM ET
      $MDCX
    • SEC Form 424B3 filed by Medicus Pharma Ltd.

      424B3 - Medicus Pharma Ltd. (0001997296) (Filer)

      5/13/25 8:18:18 AM ET
      $MDCX

    $MDCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

      PHILADELPHIA, March 06, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC). The SKNJCT-003 clinical study is currently underway in nine (9) clinical sites in United States and is expected to randomize 60 patients. The interim analysis was conducted after more than 50% of the targeted 60 patients in the study were randomized. The interim analysis shows the clinical study SKNJCT-003 is trending positively with a proportion of subjects with complete clinical clearance of more than 60%. The

      3/6/25 7:30:00 AM ET
      $MDCX
    • Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

      PHILADELPHIA, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") is pleased to announce that it has submitted a clinical design (SKNJCT-004) to UAE DOH to non-invasively treat BCC of the skin. The study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. Clinical Trial Desig

      2/27/25 7:30:00 AM ET
      $MDCX
    • Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

      PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is currently underway in nine (9) clinical sites in United States, has now randomized more than 50% of the 60 patients expected to be enrolled in the study. The Company also announced that it is on track to complete an interim data analysis before the end of Q1 2025 and to submit its findings to the United States Food and Drug Administration (FDA) as part of a package seeking a Type C meeting with the FDA in Q2 2025. The purpose of the Type C meeting is to formally discuss the product development and

      2/14/25 7:30:00 AM ET
      $MDCX

    $MDCX
    Leadership Updates

    Live Leadership Updates

    See more
    • Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

      TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

      11/18/24 7:30:00 AM ET
      $GSK
      $MDCX
      Biotechnology: Pharmaceutical Preparations
      Health Care